Skip to main content
. Author manuscript; available in PMC: 2020 Nov 11.
Published in final edited form as: Cancer Cell. 2019 Nov 11;36(5):471–482. doi: 10.1016/j.ccell.2019.09.006

Table 2.

Comparison of Characteristics of Therapy with PD-1 DNR CAR T Cells vs. Checkpoint Blockade Agents with CAR T cells

Characteristic PD-1 DNR CAR T cells CPB Agents with CAR T cells
Mechanism Cell-intrinsic Cell-extrinsic
Potential doses Single Multiple doses of CPB
Targeted therapy Yes No
Potential toxicity Localized to tumor Systemic
Limits to tumor penetration Unlikely Limits of antibody penetration
Antigen responsiveness Multiple Multiple